Comparative Pharmacology
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus ORGARAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus ORGARAN.
FONDAPARINUX SODIUM vs ORGARAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fondaparinux is a synthetic pentasaccharide that selectively binds to antithrombin III, potentiating its inhibition of factor Xa. This prevents thrombin generation and clot formation.
Danaparoid is a low molecular weight heparinoid that exerts its anticoagulant effect by inhibiting factor Xa and, to a lesser extent, factor IIa (thrombin) through binding to antithrombin III and heparin cofactor II.
2.5 mg subcutaneously once daily for prophylaxis; 5 mg (body weight <50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg) subcutaneously once daily for treatment of venous thromboembolism
Adults: Initial intravenous bolus of 2500 IU (anti-Xa), followed by continuous intravenous infusion of 400 IU/h for 2 hours, then 300 IU/h for 2 hours, then 200 IU/h for 5 days; or subcutaneous injection of 750 IU twice daily. Dose adjusted to maintain anti-Xa levels of 0.5-1.0 IU/mL.
None Documented
None Documented
Terminal elimination half-life: 17-21 hours (young adults), 21-24 hours (elderly). Provides once-daily dosing for thromboprophylaxis.
Terminal elimination half-life: 18-25 hours (mean ~19 hours) in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe renal failure, CrCl <30 mL/min).
Renal: 80-87% unchanged in urine; biliary/fecal: minimal (<10%)
Renal: 40-50% as unchanged drug; biliary/fecal: minimal; small amount metabolized via desulfation and N-acetylation.
Category C
Category C
Anticoagulant
Anticoagulant